Eveline Wallenburg
Overview
Explore the profile of Eveline Wallenburg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
44
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wallenburg E, Ter Heine R, Schouten J, Raaijmakers J, Ten Oever J, Kolwijck E, et al.
Clin Pharmacokinet
. 2022 Aug;
61(9):1325-1329.
PMID: 35947361
No abstract available.
2.
Wallenburg E, Ter Heine R, Schouten J, Raaijmakers J, Ten Oever J, Kolwijck E, et al.
Clin Pharmacokinet
. 2022 Apr;
61(6):907-918.
PMID: 35377133
Background And Objectives: Although dose optimization studies have been performed for piperacillin and tazobactam separately, a combined integral analysis is not yet reported. As piperacillin and tazobactam pharmacokinetics are likely...
3.
Gompelman M, Jager N, Wallenburg E, Bruggemann R, Bleeker-Rovers C, Wanten G
Eur J Drug Metab Pharmacokinet
. 2021 Sep;
46(6):821-823.
PMID: 34491533
No abstract available.
4.
Wallenburg E, Ter Heine R, de Lange D, van Leeuwen H, Schouten J, Ten Oever J, et al.
J Antimicrob Chemother
. 2021 Aug;
76(12):3220-3228.
PMID: 34463730
Objectives: To describe the unbound and total flucloxacillin pharmacokinetics in critically ill patients and to define optimal dosing strategies. Patients And Methods: Observational multicentre study including a total of 33...
5.
A meta-analysis of protein binding of flucloxacillin in healthy volunteers and hospitalized patients
Wallenburg E, Bruggemann R, Roberts J, Jager N, Ulldemolins M, Wilkes S, et al.
Clin Microbiol Infect
. 2021 Jul;
28(3):446.e1-446.e7.
PMID: 34245903
Objectives: The aim of this study was to develop a mechanistic protein-binding model to predict the unbound flucloxacillin concentrations in different patient populations. Methods: A mechanistic protein-binding model was fitted...
6.
Wallenburg E, Ter Heine R, Schouten J, Bruggemann R
Int J Antimicrob Agents
. 2020 Jun;
56(3):106062.
PMID: 32574792
Suboptimal use of antimicrobial drugs contributes to increasing antimicrobial resistance and may lead to therapeutic failure at the individual patient level. Considering the significant pharmacokinetic (PK) variation in special patient...
7.
Gieling E, Wallenburg E, Frenzel T, de Lange D, Schouten J, Ten Oever J, et al.
Clin Pharmacol Ther
. 2020 Apr;
108(4):770-774.
PMID: 32298468
The objective of the present study was to develop a dosing algorithm for ciprofloxacin based on both renal function and pathogen susceptibility in critically ill patients. In this observational prospective...
8.
Smits J, Wallenburg E, van Spanje A, van Luin M, Marijnissen R
J Clin Psychiatry
. 2017 Apr;
78(4):e413-e414.
PMID: 28448701
No abstract available.
9.
Wallenburg E, Klok B, de Jong K, de Maat M, Van Erp N, Stalpers-Konijnenburg S, et al.
Ther Drug Monit
. 2017 Apr;
39(3):269-272.
PMID: 28437285
Background: Valproic acid (VPA) is an effective antiepileptic drug and mood stabilizer. A key characteristic of VPA is its high and saturable protein binding at higher concentrations. Although the unbound...